on B.R.A.I.N. Biotechnology Research And Information Network AG (isin : DE0005203947)
BRAIN Biotech AG Secures EUR 128.88 Million Deal with Royalty Pharma
BRAIN Biotech AG has announced a significant royalty monetization deal valued up to EUR 128.88 million. This transaction involves the investigational compound deucrictibant, developed under the company’s BioIncubator. The deal includes an immediate upfront payment of EUR 18.41 million and potential regulatory and sales-related milestones totaling EUR 110.47 million.
Adriaan Moelker, CEO of BRAIN Biotech, emphasized the strategic importance of the transaction. The funds will help accelerate the company’s aim to become a top global player in the industrial enzyme market, focusing on food, beverage, and life sciences sectors.
CFO Michael Schneiders highlighted the innovative nature of royalty monetization as non-dilutive financing. He noted that the transaction’s value surpasses BRAIN Biotech's market capitalization prior to this deal, positioning the company favorably for future growth and investor interest.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all B.R.A.I.N. Biotechnology Research And Information Network AG news